International Chemical Investors Group completes acquisition of Sandoz site

Published: 1-Apr-2016
Manufacturing Ingredients Finance

Sandoz Industrial Products will be renamed Corden BioChem and will be associated with the Corden Pharma Group


International Chemical Investors Group (ICIG) has completed its acquisition of Sandoz Industrial Products, a Frankfurt-Höchst-based manufacturer of enzyme-based fermentation products and intermediates for the pharmaceutical industry, from Novartis Group.

Sandoz Industrial Products will be renamed Corden BioChem and will be associated with the Corden Pharma Group, the pharmaceutical platform of ICIG.

Corden BioChem will be complementary to both ICIG's pharma activities as well as its fine chemicals activities within the WeylChem Group. The site represents an important additional building block of fermentation-based production technology for ICIG.

ICIG is focused on the continuation and further development of Cordon BioChem with the enzymatic 7-ACA business for antibiotics at the Höchst site, serving customers worldwide as well as the Corden Pharma Latina site in Italy.

  • Companies:
  • CordenPharma
  • Novartis
See more

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

Read more
The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe

Trending Articles

  1. Catalent Boston adds to oral spray drying capacity to support late-stage clinical trials and commercialisation Catalent, the leading provider of oral drug development solutions, bioavailability enhancing technologies and flexible manufacturing, has completed a series of upgrades to its large-scale spray drying unit (GEA PSD-4) at its Boston (MA, US) facility
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  4. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

CordenPharma commences a €900m peptide platform expansion in the US & Europe

The expansion of CordenPharma's peptide manufacturing capabilities will serve the GLP-1 agonist market in the US, while offering end-to-end peptide manufacturing solutions in Europe
Manufacturing

Wacker and CordenPharma expand vaccine production capacity, enhancing ‘pandemic readiness’

The expansion follows an initiative the German government have launched to be 'pandemic ready', and boosts the duo's mRNA vaccine manufacturing capabilities
Manufacturing

CordenPharma and Certest partner to showcase the potential of ionisable lipids in LNP formulation

The agreement gives CordenPharma access to Certest's ionisable lipids platform, extending the company's ability to assist with the discovery, development and manufacturing of xRNA and xDNA
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Design & Build

CordenPharma expands early clinical peptide manufacturing offering

CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers
Manufacturing

CordenPharma launches lipid nanoparticle starter kits

The kits will aid in loss mitigation of high-value payloads during the gene editing journey to market
Finance

Calypso enters into agreement to be acquired by Novartis

The acquisition of Calypso gives Novartis full rights to CALY-002, a pipeline-in-a-drug with potential in dermatology, gastrointestinal and rheumatology indications
Subscribe now